Form 8-K - Current report:
SEC Accession No. 0001493152-23-033356
Filing Date
2023-09-21
Accepted
2023-09-21 16:39:39
Documents
14
Period of Report
2023-09-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 62447
2 EPIQ SCRIPTS CONSULTING AGREEMENT ex10-1.htm EX-10.1 82323
3 1ST AMENDMENT TO MSA WITH EPIQ SCRIPTS ex10-3.htm EX-10.3 69626
  Complete submission text file 0001493152-23-033356.txt   425235

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE mgrx-20230915.xsd EX-101.SCH 3012
5 XBRL LABEL FILE mgrx-20230915_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE mgrx-20230915_pre.xml EX-101.PRE 22357
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3464
Mailing Address 15110 DALLAS PKWY, SUITE 600 DALLAS TX 75248
Business Address 15110 DALLAS PKWY, SUITE 600 DALLAS TX 75248 (833) 626-4679
MANGOCEUTICALS, INC. (Filer) CIK: 0001938046 (see all company filings)

EIN.: 873841292 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41615 | Film No.: 231269509
SIC: 8090 Services-Misc Health & Allied Services, NEC